Developer docs
API playgroundTry for free, no card

Search company profiles

Lento Bio

Full company profile

uuid000cccy

Namestring
Lento Bio
Legal namestring
Lento Bio, Inc.
Websiteurl
lentobio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Lento Bio, Inc. is a privately held, preclinical-stage pharmaceutical company founded in 2022 as a Delaware C-Corporation and headquartered in Syracuse, New York within an Ichor Life Sciences biotech incubator facility. The company develops small-molecule therapeutics that target the molecular damage underlying age-related vision loss, with a primary focus on presbyopia, a universal, age-driven loss of near vision affecting approximately 1.8 billion people worldwide.

The company's lead asset, LB-01, is a topical eye drop prodrug designed to cross the cornea intact and convert to an active monothiol inside the eye that cleaves aberrant disulfide crosslinks and advanced glycation end products (AGEs) in the crystalline lens. The mechanism is intended to restore lens flexibility and natural accommodation, reversing the root cause of presbyopia rather than managing symptoms. In preclinical studies the company reports 51% rejuvenation of lens flexibility in a mouse in vivo model (p<0.0001 versus vehicle) and 41% restoration of human lens flexibility ex vivo after two days of treatment, and states superiority over the LACE asset (acquired for $465 million in 2016) across three independent assays. Lento Bio's pipeline additionally includes LB-01C, a topical formulation for cataract prevention, and LB-02, a small-molecule program for presbyopia in discovery.

Lento Bio is pre-revenue and has not yet filed for regulatory approval of any product. It is advancing LB-01 toward IND-enabling studies using proceeds from a $680,000 pre-seed round in September 2022 and an approximately $2.9 million Seed Stage A round in November 2025. The company is a portfolio company of Ichor Life Sciences, which serves as both a strategic incubator and an investor, and operates a medicinal chemistry collaboration with Dr. James Frederich's laboratory at Florida State University. Once LB-01 or any pipeline candidate reaches commercialization, distribution would follow standard prescription pharmaceutical channels; no commercial go-to-market partnerships are currently in place.

Short descriptiontext

Lento Bio is a preclinical pharmaceutical company developing topical small-molecule therapeutics that reverse molecular crosslinks in the aging eye lens, with lead candidate LB-01 targeting presbyopia in approximately 1.8 billion affected individuals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSyracuse, United States
HQ citystring
Syracuse
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic therapeutics, presbyopia treatment, small molecule drugs, lens repair, age-related disease
Industry2 codes
PRIMARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmic Therapeutics
Social media profiles2 records
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lento Bio is developing small-molecule therapeutics that repair molecular damage in the aging eye, beginning with LB-01, a topical eye drop prodrug that crosses the cornea and cleaves aberrant disulfide and AGE crosslinks in the crystalline lens to restore natural accommodation lost to presbyopia. The pipeline extends the same lens-softening platform to LB-01C (cataract prevention) and LB-02 (presbyopia), all currently in preclinical or IND-enabling stages.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 51% rejuvenation of lens flexibility in vivo mouse model (p<0.0001 vs vehicle)
+2 more records
Product overview1 text field

Lento Bio is a preclinical pharmaceutical company developing a pipeline of small molecule therapeutics for age-related ophthalmic conditions. The company's lead product is LB-01, a topical eye drop prodrug for presbyopia that works by restoring lens flexibility through reversal of molecular crosslinks. LB-01 is currently in IND-enabling studies. The pipeline also includes LB-01C (cataract prevention) and LB-02 (presbyopia), representing a platform approach to treating lens aging through anti-glycation and crosslink-cleaving mechanisms.

Product and service3 records
1LB-01
CategoryCore product — presbyopia therapeutic
Description

A first-in-class topical eye drop prodrug for presbyopia that crosses the cornea intact and converts to active drug inside the eye, where it cleaves aberrant disulfide and AGE crosslinks that stiffen the crystalline lens to restore natural accommodation. Currently in IND-enabling studies.

2LB-01C
CategoryPipeline product — cataract prevention therapeutic
Description

A topical eye drop formulation in development for cataract prevention, applying Lento Bio's anti-glycation and crosslink-cleaving platform to cataract indications; currently in preclinical stage.

3LB-02
CategoryPipeline product — presbyopia therapeutic
Description

A small molecule therapeutic in discovery phase for presbyopia, representing pipeline expansion beyond the LB-01 lead asset using an additional lens-aging mechanism.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-06
Description

Official medicinal chemistry collaboration with Dr. James Frederich's lab at Florida State University. The collaboration focuses on developing novel variants of Lento Bio's lead compounds to optimize the eyedrop for reducing lens stiffness and treating presbyopia. The lab also synthesizes de novo compounds to potentially expand Lento Bio's pipeline. Dr. Frederich heads an NIH-funded research laboratory with expertise in developing complex natural products that modulate protein-protein interactions, with over $3 million in federal funding.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-06
Description

Lento Bio is an Ichor Life Sciences portfolio company, incubated and supported by Ichor's preclinical contract research organization. Ichor provides shared infrastructure, scientific talent, laboratory space, and collaborative ecosystem purpose-built for early-stage therapeutics development. Ichor CEO Dr. Kelsey Moody and CSO Dr. Aaron Wolfe have served as strategic advisors since Lento Bio's founding in 2022. Ichor led the $680,000 seed round with $400,000 investment and participated in the ~$2.9M Seed Stage A round. Lento Bio relocated to Ichor's new biotech incubator facility in Syracuse, NY in June 2024.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-06-06
Description

Lento Bio was initially incubated at Clarkson University's Peyton Hall Biotechnology Incubator in Potsdam, NY at the time of its launch in June 2022. The company was the first startup company to join Ichor Life Sciences in establishing a North Country biotechnology cluster. Lento Bio relocated from this facility in June 2024 to Ichor's new Syracuse location.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AbbVie's Allergan Aesthetics division developed and markets Vuity (pilocarpine), the first FDA-approved eye drop for presbyopia. Direct competitor in the presbyopia therapeutics category, with established commercial infrastructure and physician adoption that Lento Bio will need to compete against at launch.

TypeDirect peer
Description

Clinical-stage ophthalmology company developing CSF-1 (pilocarpine-based) eye drop for presbyopia. Direct peer targeting the same patient population and prescriber channel, though via a miotic mechanism rather than Lento Bio's lens-softening approach.

TypeDirect peer
Description

Clinical-stage ophthalmic company developing BRIMOCHOL and BRIMOCHOL PF, investigational presbyopia eye drops. Direct competitor in presbyopia therapeutics with active late-stage clinical programs and overlapping prescriber targets.

TypeDirect peer
Description

Ophthalmic therapeutics company developing MicroLine (pilocarpine delivered via Optejet dispenser) for presbyopia. Direct peer developing eye-drop-based presbyopia therapeutics with proprietary delivery technology.

TypeDirect peer
Description

Late-clinical-stage ophthalmic company developing Nyxol (phentolamine) for presbyopia and other refractive indications. Direct competitor in presbyopia with active Phase 3 program targeting the same prescriber base.

TypeBroad incumbent
Description

Established ophthalmic medical device and pharmaceutical company focused primarily on glaucoma, with expanding presence in broader ophthalmic therapeutics. Comparable as a publicly traded ophthalmology innovator with infrastructure Lento Bio would need at commercial scale.

TypeBroad incumbent
Description

Diversified global ophthalmology company with established vision care and ophthalmic pharmaceuticals franchises. Comparable as a broad incumbent with reading-glasses (Biotrue, PreserVision) and emerging presbyopia-relevant product lines that overlap with Lento Bio's target market.

TypeEmerging player
Description

Early-clinical-stage ophthalmology company developing polyCol peptide therapeutics targeting collagen-damaging diseases including dry eye and potentially presbyopia-related lens pathology. Comparable as a small, lens-and-ocular-surface-focused emerging therapeutics developer.

TypeEmerging player
Description

Clinical-stage biotechnology company developing novel small-molecule therapies for ocular and systemic inflammatory diseases. Comparable as a small-molecule-focused ophthalmic biotech at a similar stage of clinical maturity to where Lento Bio is heading.

TypeEmerging player
Description

Ophthalmic pharmaceutical company focused on small-molecule therapeutics for glaucoma, dry eye, and retinal diseases (Rocklatan, Rhopressa). Comparable as a small-molecule ophthalmology biotech with established commercial experience relevant to Lento Bio's future launch pathway.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lento Bio

Ophthalmic Therapeuticslentobio.com

Lento Bio is a preclinical pharmaceutical company developing topical small-molecule therapeutics that reverse molecular crosslinks in the aging eye lens, with lead candidate LB-01 targeting presbyopia in approximately 1.8 billion affected individuals.

What Lento Bio does

Lento Bio, Inc. is a privately held, preclinical-stage pharmaceutical company founded in 2022 as a Delaware C-Corporation and headquartered in Syracuse, New York within an Ichor Life Sciences biotech incubator facility. The company develops small-molecule therapeutics that target the molecular damage underlying age-related vision loss, with a primary focus on presbyopia, a universal, age-driven loss of near vision affecting approximately 1.8 billion people worldwide.

The company's lead asset, LB-01, is a topical eye drop prodrug designed to cross the cornea intact and convert to an active monothiol inside the eye that cleaves aberrant disulfide crosslinks and advanced glycation end products (AGEs) in the crystalline lens. The mechanism is intended to restore lens flexibility and natural accommodation, reversing the root cause of presbyopia rather than managing symptoms. In preclinical studies the company reports 51% rejuvenation of lens flexibility in a mouse in vivo model (p<0.0001 versus vehicle) and 41% restoration of human lens flexibility ex vivo after two days of treatment, and states superiority over the LACE asset (acquired for $465 million in 2016) across three independent assays. Lento Bio's pipeline additionally includes LB-01C, a topical formulation for cataract prevention, and LB-02, a small-molecule program for presbyopia in discovery.

Lento Bio is pre-revenue and has not yet filed for regulatory approval of any product. It is advancing LB-01 toward IND-enabling studies using proceeds from a $680,000 pre-seed round in September 2022 and an approximately $2.9 million Seed Stage A round in November 2025. The company is a portfolio company of Ichor Life Sciences, which serves as both a strategic incubator and an investor, and operates a medicinal chemistry collaboration with Dr. James Frederich's laboratory at Florida State University. Once LB-01 or any pipeline candidate reaches commercialization, distribution would follow standard prescription pharmaceutical channels; no commercial go-to-market partnerships are currently in place.

Lento Bio firmographics

Firmographics
Name
Lento Bio
Legal name
Lento Bio, Inc.
Website
https://lentobio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Lento Bio is a preclinical pharmaceutical company developing topical small-molecule therapeutics that reverse molecular crosslinks in the aging eye lens, with lead candidate LB-01 targeting presbyopia in approximately 1.8 billion affected individuals.
Ownership category
akta.pro rank

Lento Bio industry classification

Industry
Product category
Ophthalmic Therapeutics
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)

Keywords

  • Ophthalmic therapeutics
  • Presbyopia treatment
  • Small molecule drugs
  • Lens repair
  • Age-related disease

Where Lento Bio is headquartered

Location

Headquarters

HQ city
Syracuse
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lento Bio business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Marketing channels2 records

Lento Bio product offering

Product offering

Core offering

Lento Bio is developing small-molecule therapeutics that repair molecular damage in the aging eye, beginning with LB-01, a topical eye drop prodrug that crosses the cornea and cleaves aberrant disulfide and AGE crosslinks in the crystalline lens to restore natural accommodation lost to presbyopia. The pipeline extends the same lens-softening platform to LB-01C (cataract prevention) and LB-02 (presbyopia), all currently in preclinical or IND-enabling stages.

Product overview

Lento Bio is a preclinical pharmaceutical company developing a pipeline of small molecule therapeutics for age-related ophthalmic conditions. The company's lead product is LB-01, a topical eye drop prodrug for presbyopia that works by restoring lens flexibility through reversal of molecular crosslinks. LB-01 is currently in IND-enabling studies. The pipeline also includes LB-01C (cataract prevention) and LB-02 (presbyopia), representing a platform approach to treating lens aging through anti-glycation and crosslink-cleaving mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

  • LB-01 A first-in-class topical eye drop prodrug for presbyopia that crosses the cornea intact and converts to active drug inside the eye, where it cleaves aberrant disulfide and AGE crosslinks that stiffen the crystalline lens to restore natural accommodation. Currently in IND-enabling studies.
  • LB-01C A topical eye drop formulation in development for cataract prevention, applying Lento Bio's anti-glycation and crosslink-cleaving platform to cataract indications; currently in preclinical stage.
  • LB-02 A small molecule therapeutic in discovery phase for presbyopia, representing pipeline expansion beyond the LB-01 lead asset using an additional lens-aging mechanism.

Quantifiable outcome

  • 51% rejuvenation of lens flexibility in vivo mouse model (p<0.0001 vs vehicle)
  • +2 more outcomes

Companies that use Lento Bio

Customer profile

Segments1 record

Ideal customer profiles2 records

Lento Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Lento Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Florida State UniversitycoreStrategic or Co-development Partner · 6 February 2023Official medicinal chemistry collaboration with Dr. James Frederich's lab at Florida State University. The collaboration focuses on developing novel variants of Lento Bio's lead compounds to optimize the eyedrop for reducing lens stiffness and treating presbyopia. The lab also synthesizes de novo compounds to potentially expand Lento Bio's pipeline. Dr. Frederich heads an NIH-funded research laboratory with expertise in developing complex natural products that modulate protein-protein interactions, with over $3 million in federal funding.
  • Ichor Life SciencescoreStrategic or Co-development Partner · 6 June 2022Lento Bio is an Ichor Life Sciences portfolio company, incubated and supported by Ichor's preclinical contract research organization. Ichor provides shared infrastructure, scientific talent, laboratory space, and collaborative ecosystem purpose-built for early-stage therapeutics development. Ichor CEO Dr. Kelsey Moody and CSO Dr. Aaron Wolfe have served as strategic advisors since Lento Bio's founding in 2022. Ichor led the $680,000 seed round with $400,000 investment and participated in the ~$2.9M Seed Stage A round. Lento Bio relocated to Ichor's new biotech incubator facility in Syracuse, NY in June 2024.
  • Clarkson UniversityminorStrategic or Co-development Partner · 6 June 2022Lento Bio was initially incubated at Clarkson University's Peyton Hall Biotechnology Incubator in Potsdam, NY at the time of its launch in June 2022. The company was the first startup company to join Ichor Life Sciences in establishing a North Country biotechnology cluster. Lento Bio relocated from this facility in June 2024 to Ichor's new Syracuse location.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Lento Bio competitors and assessment

Company assessment

Direct peers

  • AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics division developed and markets Vuity (pilocarpine), the first FDA-approved eye drop for presbyopia. Direct competitor in the presbyopia therapeutics category, with established commercial infrastructure and physician adoption that Lento Bio will need to compete against at launch.
  • Orasis Pharmaceuticals: Clinical-stage ophthalmology company developing CSF-1 (pilocarpine-based) eye drop for presbyopia. Direct peer targeting the same patient population and prescriber channel, though via a miotic mechanism rather than Lento Bio's lens-softening approach.
  • Visus Therapeutics: Clinical-stage ophthalmic company developing BRIMOCHOL and BRIMOCHOL PF, investigational presbyopia eye drops. Direct competitor in presbyopia therapeutics with active late-stage clinical programs and overlapping prescriber targets.
  • Eyenovia: Ophthalmic therapeutics company developing MicroLine (pilocarpine delivered via Optejet dispenser) for presbyopia. Direct peer developing eye-drop-based presbyopia therapeutics with proprietary delivery technology.
  • Ocuphire Pharma: Late-clinical-stage ophthalmic company developing Nyxol (phentolamine) for presbyopia and other refractive indications. Direct competitor in presbyopia with active Phase 3 program targeting the same prescriber base.

Broad incumbents

  • Glaukos Corporation: Established ophthalmic medical device and pharmaceutical company focused primarily on glaucoma, with expanding presence in broader ophthalmic therapeutics. Comparable as a publicly traded ophthalmology innovator with infrastructure Lento Bio would need at commercial scale.
  • Bausch + Lomb: Diversified global ophthalmology company with established vision care and ophthalmic pharmaceuticals franchises. Comparable as a broad incumbent with reading-glasses (Biotrue, PreserVision) and emerging presbyopia-relevant product lines that overlap with Lento Bio's target market.

Emerging players

  • Stuart Therapeutics: Early-clinical-stage ophthalmology company developing polyCol peptide therapeutics targeting collagen-damaging diseases including dry eye and potentially presbyopia-related lens pathology. Comparable as a small, lens-and-ocular-surface-focused emerging therapeutics developer.
  • Aldeyra Therapeutics: Clinical-stage biotechnology company developing novel small-molecule therapies for ocular and systemic inflammatory diseases. Comparable as a small-molecule-focused ophthalmic biotech at a similar stage of clinical maturity to where Lento Bio is heading.
  • Aerie Pharmaceuticals: Ophthalmic pharmaceutical company focused on small-molecule therapeutics for glaucoma, dry eye, and retinal diseases (Rocklatan, Rhopressa). Comparable as a small-molecule ophthalmology biotech with established commercial experience relevant to Lento Bio's future launch pathway.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Lento Bio social profiles

Digital presence

Lento Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lento Bio leadership team

Management profile

Number of profiles

Profiles10 records

Lento Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lento Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lento Bio

What does Lento Bio do?

Lento Bio is developing small-molecule therapeutics that repair molecular damage in the aging eye, beginning with LB-01, a topical eye drop prodrug that crosses the cornea and cleaves aberrant disulfide and AGE crosslinks in the crystalline lens to restore natural accommodation lost to presbyopia. The pipeline extends the same lens-softening platform to LB-01C (cataract prevention) and LB-02 (presbyopia), all currently in preclinical or IND-enabling stages.

Is Lento Bio a public or private company?

Lento Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lento Bio founded?

Lento Bio was founded in 2022. It employs 1 to 10 people.

Where is Lento Bio based?

Lento Bio is headquartered in Syracuse, United States, in the North America region.

Who are Lento Bio's main competitors?

Direct peers on record are AbbVie (Allergan Aesthetics), Orasis Pharmaceuticals, Visus Therapeutics, Eyenovia and Ocuphire Pharma. Broad incumbents are Glaukos Corporation and Bausch + Lomb. Emerging players are Stuart Therapeutics, Aldeyra Therapeutics and Aerie Pharmaceuticals.

Does Lento Bio have an API?

No public API is recorded for Lento Bio.

What industry is Lento Bio in?

Lento Bio's product category is Ophthalmic Therapeutics. Its primary akta.pro industry code is HLAAAGAK, Ophthalmic Regeneration (cornea/retina), with a secondary code of HLAKAKAF, Cornea, External Disease & Refractive Surgery (LASIK/PRK). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales